Press Releases April 29, 2026 09:00 AM

Hawkins, Inc. to Release Fourth Quarter and Fiscal 2026 Financial Results on May 13, 2026

Hawkins, Inc. announces Q4 and Fiscal 2026 earnings release date of May 13, 2026

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
HWKN

Hawkins, Inc., a Minnesota-based water treatment and specialty ingredients company, announced it will release its fourth quarter and full fiscal year 2026 financial results on May 13, 2026, after market close. The company serves Water Treatment, Food & Health Sciences, and Industrial Solutions sectors and generated $974 million in revenue in fiscal 2025.

Hawkins, Inc. to Release Fourth Quarter and Fiscal 2026 Financial Results on May 13, 2026
HWKN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Hawkins will report Q4 and full fiscal 2026 results on May 13, 2026.
  • The company operates 65 facilities across 28 U.S. states with approximately 1,100 employees.
  • Focus sectors include water treatment, food & health sciences, and industrial solutions, impacting specialty chemicals and industrial services markets.

Roseville, Minn., April 29, 2026 (GLOBE NEWSWIRE) -- Hawkins, Inc. (Nasdaq: HWKN) announced today that it expects to release its financial results for its fourth quarter and fiscal year ended March 29, 2026 after the market closes on May 13, 2026 at approximately 4:10 p.m. Eastern Time. 

About Hawkins, Inc.

Hawkins, Inc. was founded in 1938 and is a leading water treatment and specialty ingredients company that formulates, manufactures, distributes, and blends products for its Water Treatment, Food & Health Sciences and Industrial Solutions customers. Headquartered in Roseville, Minnesota, the Company has 65 facilities in 28 states and creates value for its customers through superb customer service and support, quality products and personalized applications. Hawkins, Inc. generated $974 million of revenue in fiscal 2025 and has approximately 1,100 employees. For more information, including registering to receive email alerts, please visit www.hawkinsinc.com/investors.

Contact:               Jeffrey P. Oldenkamp    
                             Executive Vice President and Chief Financial Officer
                             612/331-6910                    
                             ir@hawkinsinc.com


Risks

  • Potential risks include general market volatility around quarterly earnings announcements affecting stock price.
  • Industry-specific risks such as fluctuations in demand for specialty chemicals and industrial ingredients.
  • Operational risks tied to maintaining consistent product quality and supply chain efficiency across multiple locations.

More from Press Releases

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026